Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Rhea-AI Summary

Tempest Therapeutics (Nasdaq: TPST) announced two poster presentations at the 2022 AACR virtual annual meeting scheduled for April 8-13, 2022. The presentations feature new preclinical data on TPST-1495, a clinical-stage dual EP2/4 antagonist, and TREX1, a preclinical STING agonist. Key presentations include: TPST-1495 focusing on the dual blockade of PGE2 receptors and TREX1 aimed at activating STING in metastatic disease. Both programs are designed to enhance tumor treatment via targeted and immune-mediated approaches.

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced two poster presentations at the 2022 American Association for Cancer Research (AACR) virtual annual meeting taking place April 8-13, 2022. The presentations contain new preclinical data for two of Tempest’s small molecule programs, TPST-1495 (clinical-stage dual EP2/4 antagonist) and TREX1 (preclinical STING agonist).

Details:

Title: Dual Blockade of the EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for Drugging the Prostaglandin Pathway

Session Title: Inflammation, Tumor Intitiation and Progression
Session Date and Time: Monday April 11, 2022 9:00 a.m. – 12:30 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 36
Abstract Number: 1333

Title: Systemic Small Molecule TREX1 Inhibitors to Selectively Activicate STING in the TME of Metastatic Disease

Session Title: Immunomodulatory Agents and Interventions 1
Session Date and Time: Monday April 11, 2022 1:30 p.m. – 5:00 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
Abstract Number: 2075

Full abstracts are available for viewing in the AACR Online Itinerary Planner located here, https://www.abstractsonline.com/pp8/#!/10517.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both TPST-1120 and TPST-1495 are advancing through Phase 1 clinical trials designed to study both agents as monotherapies and in combination with other approved agents. In collaboration with F. Hoffmann La Roche, TPST-1120 is also advancing through a randomized first line, global, Phase 1b/2 clinical study in combination with the standard-of-care regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contact:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media Contact:

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@tempesttx.com

---

¹ If approved

FAQ

What is Tempest Therapeutics presenting at the 2022 AACR annual meeting?

Tempest Therapeutics is presenting preclinical data on TPST-1495 and TREX1 at the 2022 AACR annual meeting.

When is Tempest Therapeutics' presentation on TPST-1495?

The presentation on TPST-1495 is scheduled for April 11, 2022, from 9:00 a.m. to 12:30 p.m. CST.

What is the focus of the TPST-1495 presentation?

The focus is on the dual blockade of the EP2 and EP4 PGE2 receptors as an optimal approach for drugging the prostaglandin pathway.

What time is the TREX1 presentation during the AACR annual meeting?

TREX1 will be presented on April 11, 2022, from 1:30 p.m. to 5:00 p.m. CST.

What is the significance of the TREX1 presentation?

The TREX1 presentation discusses systemic small molecule inhibitors that selectively activate STING in the tumor microenvironment of metastatic disease.